Iloprost modulates the immune response in systemic sclerosis

BMC Immunology

Volumn 11, Issue , 2010, Pages

  D'Amelio, Patrizia ^a   Cristofaro, Maria A ^a   D'Amico, Lucia ^b   Veneziano, Luciana ^a   Roato, Ilaria ^b   Sassi, Francesca ^a   Bisignano, Giuseppina ^a   Saracco, Marta ^c   Pellerito, Raffaele ^c   Patanè, Salvatore ^b   Ferracini, Riccardo ^b   Pescarmona, Gian P ^a,b   Isaia, Giovanni C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AOU San Giovanni Battista   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ILOPROST; INTERLEUKIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGIC FACTOR; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MONOCYTE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SYSTEMIC SCLEROSIS; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

FEMALE; HUMANS; ILOPROST; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; MIDDLE AGED; PHYTOHEMAGGLUTININS; RANK LIGAND; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650036793     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-62     Document Type: Article

References (36)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004, 140:37-50.
2. Hussein MR, Hassan HI, Hofny ER, Elkholy M, Fatehy NA, Abd Elmoniem AE, Ezz El-Din AM, Afifi OA, Rashed HG. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005, 58:178-84. 10.1136/jcp.2004.019224, 1770564, 15677539.
3. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-5. 10.1136/ard.2004.027094, 1755597, 16014686.
4. Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007, 56:3459-67. 10.1002/art.22927, 17907151.
5. Gustafsson R, Totterman TH, Klareskog L, Hallgren R. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 1990, 49:40-5. 10.1136/ard.49.1.40, 1003962, 2138008.
6. Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, Bernardini G, Strom R, Taccari E, Valesini G. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 2005, 32:283-6.
7. Del Galdo F, Jimenez SA. T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis Rheum 2007, 56:3478-88. 10.1002/art.22877, 17907195.
8. Fujii H, Hasegawa M, Takehara K, Mukaida N, Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002, 130:548-56. 10.1046/j.1365-2249.2002.02017.x, 1906557, 12452848.
9. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009, 16:274-9. 10.1097/MOH.0b013e32832a9a01, 19417650.
10. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, Hussaini A, Simms R, Cruikshank WW, Lafyatis R. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 2009, 4:e5981. 10.1371/journal.pone.0005981, 2695559, 19543397.
11. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii19-24. 10.1093/rheumatology/kep105, 19487218.
12. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199-206.
13. Korn JH, Halushka PV, LeRoy EC. Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J Clin Invest 1980, 65:543-54. 10.1172/JCI109698, 371393, 7356693.
14. Goldstein RH, Polgar P. The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts. J Biol Chem 1982, 257:8630-3.
15. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001, 108:241-50. 203022, 11457877.
16. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. Faseb J 2002, 16:1949-51.
17. Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26:2159-67.
18. Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003, 33:1013-7. 10.1046/j.1365-2362.2003.01241.x, 14636306.
19. Jorres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 1997, 9:119-25. 10.1006/cyto.1996.0145, 9071563.
20. Zhou W, Blackwell TS, Goleniewska K, F O'Neal J, Fitzgerald GA, Lucitt M, Breyer RM, Peebles RS. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J Leukoc Biol 2007, 81:809-17. 10.1189/jlb.0606375, 17135575.
21. Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, Geraci MW, Peebles RS. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007, 178:702-10.
22. Di Renzo M, Pieragalli D, Meini S, De Franco V, Pompella G, Auteri A, Pasqui AL. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids 2005, 73:405-10. 10.1016/j.plefa.2005.05.025, 16095891.
23. Jaffar Z, Wan KS, Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J Immunol 2002, 169:5997-6004.
24. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-50. 10.1196/annals.1443.016, 19076348.
25. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008, 26:453-79. 10.1146/annurev.immunol.26.021607.090357, 18062768.
26. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-69. 10.1038/nri2448, 2724991, 19029990.
27. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009, 31:539-50. 10.1016/j.immuni.2009.09.002, 2774226, 19833085.
28. Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, Zhou W, Goleniewska K, O'Neal JF, Morrow JD, Durbin RK, Wright PF, Collins RD, Suzutani T, Peebles RS. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol 2004, 78:10303-9. 10.1128/JVI.78.19.10303-10309.2004, 516432, 15367596.
29. Nagao K, Tanaka H, Komai M, Masuda T, Narumiya S, Nagai H. Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. Am J Respir Cell Mol Biol 2003, 29:314-20. 10.1165/rcmb.2003-0035OC, 12676807.
30. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009, 22:557-65.
31. Muller T, Durk T, Blumenthal B, Herouy Y, Sorichter S, Grimm M, Panther E, Cicko S, Norgauer J, Idzko M. Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells. Clin Exp Allergy 40:1214-21. 10.1111/j.1365-2222.2010.03558.x, 20649610.
32. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007, 117:464-72. 10.1172/JCI28949, 1783814, 17273558.
33. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-45. 10.1016/j.immuni.2009.04.010, 19464986.
34. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008, 205:1975-81. 10.1084/jem.20080308, 2526184, 18710931.
35. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea AM, Tanaseanu C, Dumitrache S, Otelea D, Tamsulea I, Tanaseanu S, Chitonu C, Paraschiv S, Balteanu M, Stefanescu M, Matache C. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009, 42:41-9. 10.1080/08916930802282651, 18800250.
36. Conaway HH, Diez LF, Raisz LG. Effects of prostacyclin and prostaglandin E1 (PGE1) on bone resorption in the presence and absence of parathyroid hormone. Calcif Tissue Int 1986, 38:130-4. 10.1007/BF02556872, 3085891.